Stockreport

G1 Therapeutics discontinue COSELA in TNBC following Phase III flop [Yahoo! Finance]

G1 Therapeutics, Inc.  (GTHX) 
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: g1therapeutics.com/pages/investors/investors.htm
PDF The North Carolina-based oncology company announced that the Phase III Preserve-2 trial did not meet the primary endpoint of overall survival (OS), with a median OS in [Read more]